A compound of Formula or a pharmaceutically acceptable salt thereof wherein R 1 is H, R 2 is C 1-5 alkyl optionally substituted with one or more hydroxyl, or R 1 and R 2, together with the nitrogen to which they are attached, form: a nitrogen containing heterocyclic ring, wherein the heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of C 1-3 alkyl, -CH 2 -OCH 3, halo, and piperazin-1-yl optionally substituted with C 1-3 alkyl on the nitrogen at the 4 position, or a bicyclic ring system selected from the group consisting of wherein each occurrence of R a and R b is independently selected from the group consisting of H, CN, halo, -CH 2 OCH 3, C 1-3 alkoxyl, and C 1-3 alkyl optionally substituted with one hydroxy group; R 3 and R 6 are each independently selected from the group consisting of H, C 1-3 alkoxyl, -O-C 1-3 haloalkyl, -O-CH 2 -C 3-6 cyclalkyl, halo, and -NR x R y, wherein R x and R y are each independently H or C 1-3 alkyl; R 4 and R 5 are each independently selected from the group consisting of H, halo, C 1-3 alkoxy, and C 1-3 alkyl, R 7 is N or CH; R 8 is selected from the group consisting of H, CN, C 1-3 haloalkyl and C 1-3 alkyl; and R 9 is selected from the group consisting of C 1-3 alkoxyl, C 1-3 haloalkyl, -O-C 1-3 haloalkyl, and -O-CH 2 -C 3-6 cycloalkyl, with the proviso that the compound of Formula is not N-propyl-4-[[4-[3,3,3-tris(fluoranyl)propyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzamide. a nitrogen containing heterocyclic ring, wherein the heterocyclic ring is optionally substituted with one or more substituents independently selected from the group consisting of C 1-3 alkyl, -CH 2 -OCH 3, halo, and piperazin-1-yl optionally substituted with C 1-3 alkyl on the nitrogen at the 4 position, or a bicyclic ring system selected from the group consisting of wherein each occurrence of R a and R b is independently selected from the group consisting of H, CN, halo, -CH 2 OCH 3, C 1-3 alkoxyl, and C 1-3 alkyl optionally substituted with one hydroxy group; R 3 and R 6 are each independently selected from the group consisting of H, C 1-3 alkoxyl, -O-C 1-3 haloalkyl, -O-CH 2 -C 3-6 cyclalkyl, halo, and -NR x R y, wherein R x and R y are each independently H or C 1-3 alkyl; R 4 and R 5 are each independently selected from the group consisting of H, halo, C 1-3 alkoxy, and C 1-3 alkyl, R 7 is N or CH; R 8 is selected from the group consisting of H, CN, C 1-3 haloalkyl and C 1-3 alkyl; and R 9 is selected from the group consisting of C 1-3 alkoxyl, C 1-3 haloalkyl, -O-C 1-3 haloalkyl, and -O-CH 2 -C 3-6 cycloalkyl, with the proviso that the compound of Formula is not N-propyl-4-[[4-[3,3,3-tris(fluoranyl)propyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzamide. R 3 and R 6 are each independently selected from the group consisting of H, C 1-3 alkoxyl, -O-C 1-3 haloalkyl, -O-CH 2 -C 3-6 cyclalkyl, halo, and -NR x R y, wherein R x and R y are each independently H or C 1-3 alkyl; R 4 and R 5 are each independently selected from the group consisting of H, halo, C 1-3 alkoxy, and C 1-3 alkyl, R 7 is N or CH; R 8 is selected from the group consisting of H, CN, C 1-3 haloalkyl and C 1-3 alkyl; and R 9 is selected from the group consisting of C 1-3 alkoxyl, C 1-3 haloalkyl, -O-C 1-3 haloalkyl, and -O-CH 2 -C 3-6 cycloalkyl, with the proviso that the compound of Formula is not N-propyl-4-[[4-[3,3,3-tris(fluoranyl)propyl]-7H-pyrrolo[2,3-d]pyrimidin-2-yl]amino]benzamide.